Pond Technologies Holdings (TSX.V: POND; OTCQB: PNDHF; FSE: 4O0), Technology leader in the cultivation of microalgae in a controlled environment, strengthens its board of directors with a real stock market heavyweight: Anthony J. Giovinazzo, C.S.C.L., M.B.A., C.B.A., C.Dir., A.C.C. was appointed to the Board of Directors with immediate effect.
Giovinazzo was the founder, CEO, and director of Cynapsus Therapeutics Inc. (Nasdaq: CYNA), which was acquired for more than $ 800 million in 2016. Currently, Giovinazzo is the managing director of Sublimity Therapeutics, a private, late-stage biopharmaceutical company specializing in gastrointestinal and autoimmune diseases. He is also a director of Titan Medical Inc. (TSX: TMD; Nasdaq: TMDI), which develops robotic technology for single-entry surgery.
Anthony Giovinazzo’s mandate will be to advise Pond CEO Grant Smith and the Board of Directors on strategy and capital market issues related to the company’s newly formed biotech division.
In 2017, Mr. Giovinazzo was the inaugural recipient of the annual Bloom Burton Award, which recognizes an individual scientist, inventor, officer, entrepreneur, industry leader or policy maker who made the greatest contribution to Canada’s innovative healthcare industry in the previous year. He is the Chartered Director (C.Dir.) And Audit Committee Certification (ACC) of Directors College and the DeGroote School of Business at McMaster University. He also completed the Advising The Public Company Board program at Osgoode Hall Law School. He received a Bachelor of Arts degree in Economics and Accounting from McMaster University, a Certificate of Studies in Canadian Law from Osgoode Hall Law School, an MBA from IMD Geneva, Switzerland, and completed the Leadership & Strategy in Pharmaceuticals & Biotech “from Harvard Business School.
Grant Smith, CEO of Pond, said, “We are very pleased to welcome Anthony Giovinazzo to our Board of Directors. Anthony Giovinazzo has a track record in drug development, licensing, private and public finance and M&A transactions and is a seasoned strategic thinker and tactician. His extensive pharmaceutical experience will be of great help to our new Pond Biotech department, which uses biopharmaceutical algae strains to express complex proteins for diagnostics and therapy. “
Pond also announces that Cameron Mingay has resigned as chairman to pursue other interests and that Robert McLeese has taken on the role of chairman of Pond. Robert McLeese, BSc., MBA, CPA, is the President of Access Personal-Financial.com Corp., a financial advisory firm that specializes in developing and financing independent energy projects in Canada and the United States. He is the CEO and Chairman of ACI Energy, an energy development and operations company that has significant interests in two US power plants, and the CEO of Cobble Beach Golf Resort Community, a golf course resort and community in Ontario. Mr. McLeese is also a director of Export Development Canada (EDC), where he serves as the chair of the audit committee.
Pond Technology, based in Markham, Ontario, is a technology leader in the cultivation of microalgae in a controlled environment. In more than ten years of research and development, Pond has developed a robust disruptive technology platform based on artificial intelligence, proprietary LED lights and patented CO2 management. Using concentrated CO2 from industrial waste streams enables Pond to increase the productivity of microalgae well beyond the capacity of outdoor algae growers, and enables industrial emitters to reduce and ultimately recycle CO2. Pond currently sells the microalgae-derived antioxidant astaxanthin under its Regenurex brand. As microalgae become increasingly important in pharmaceuticals and cosmetics, nutraceuticals, human nutrition, aquafarming, bioplastics, and biofuels, Pond has begun licensing its technology to third parties in exchange for ongoing royalties and royalties. Pond recently added a biotech division focused on growing unique strains of microalgae to be used as a reproductive medium for the expression of human antibodies and proteins.
Risk warning: GOLDINVEST Consulting GmbH publishes on https://goldinvest.de Comments, analysis and news. This content is intended solely for the information of the reader and does not represent any kind of call for action, neither explicitly nor implicitly are they to be understood as a guarantee of possible price developments. Furthermore, they are in no way a substitute for individual, expert investment advice and represent neither an offer to sell the stock (s) in question nor an invitation to buy or sell securities. This is expressly not a financial analysis but a promotional one / journalistic texts. Readers who make investment decisions or carry out transactions on the basis of the information provided here act entirely at their own risk. There is no contractual relationship between GOLDINVEST Consulting GmbH and its readers or the users of its offers, as our information only relates to the company, but not to the reader’s investment decision.
According to §34b WpHG and § 48f Abs. 5 BörseG (Austria) we would like to point out that GOLDINVEST Consulting GmbH and / or partners, clients or employees of GOLDINVEST Consulting GmbH hold shares in Pond Technologies Holdings and that there is thus a conflict of interest. GOLDINVEST Consulting GmbH also reserves the right to buy or sell shares in the company at any time. In addition, GOLDINVEST Consulting GmbH is rewarded by Pond Technologies Holdings for reporting on the company. This is another clear conflict of interest.
Note: PERSONAL-FINANCIAL.COM publishes analyzes, columns and news from various sources in this section. PERSONAL-FINANCIAL.COM AG is not responsible for content that has been recognized by third parties in the “News” area of this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and / or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.